Here is a brief preview of this blast: On Wednesday, October 27, Novartis announced (press release) that the FDA has granted Kymriah (CD19 CAR-T) Priority Review in r/r FL. Below, Celltelligence provides insights on Kymriah's anticipated US approval in ≥3L r/r FL.
About The Author
The Celltelligence Team
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.